Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

Clinical Pharmacogenetic Study of the Efficacy and Safety of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.

Inclusion Criteria:

• Age of all studied subjects ≥ 18 years old
• All patients with hepatocellular carcinoma will be included in group I.
• Patients not treated with systemic TKIs

Exclusion Criteria:

• Patients presented with liver tumors other than HCC.
• Patients with Child-Pugh grade C for liver function.
• Patients with other malignancies.
• Patients with chronic inflammatory disorders.
• Patients with severe organ dysfunction such as heart, lung, and kidney.
• Patients who cannot tolerate or are allergic to sorafenib.
• Patients with severe coagulation dysfunction were uncorrectable.
• Age less than 18 years old.